Neurode

Neurode operates at the intersection of digital therapeutics, medical devices, wearable computing, and brain-computer interface research. Its initial market is ADHD and adjacent neurological-care use cases, rather than general wellness: the company describes a drug-free, personalised approach supported by a wearable, brain monitoring, and a clinician-facing data loop. That positioning differentiates Neurode from conventional consumer wearables that primarily track activity or sleep, but it also places the company in a more demanding category requiring clinical validation, regulatory clarity, and evidence that measured signals translate into meaningful outcomes. The Neurode Wave combines optical systems, functional near-infrared spectroscopy research, signal-detection algorithms, and BCI concepts, giving it a more specialised technical profile than standard attention or productivity devices. Its competitive advantages are therefore best assessed as product and execution hypotheses rather than established market leadership: firsthand ADHD experience among the founding team, an integrated hardware-and-app model, and progress toward clinical evaluation. The company’s $13.5 million in recorded funding provides meaningful support for this development path, while its small employee footprint indicates that commercial scale remains unproven.

Neurode’s trajectory shows a progression from early hardware and neuroscience development to a more heavily funded product-validation phase. By Dec 22, 2023, Neurode had a patent publication covering systems and methods for monitoring neurological symptoms, indicating continued investment in its technical and intellectual-property base. The next financing inflection point came on Sep 13, 2024, when the company recorded a $3.5 million pre-seed round involving Khosla Ventures and PsyMed Ventures. A further $10 million seed round on May 8, 2025 lifted cumulative recorded funding to $13.5 million and represents the strongest evidence of acceleration. The product has evolved around the Neurode Wave wearable and a companion application designed to monitor progress and share information with clinicians. Website positioning says the product moved from initial concept to clinical evaluation in under three years, suggesting a shift from research and prototyping toward evidence generation. Neurode remains a small organisation with two featured current positions and an employee range of 1–10, so the next trajectory test is converting financing and technical assets into validated clinical outcomes, regulatory progress, and repeatable commercial adoption.